Editas Medicine: Primed For An Unlikely Comeback? It's Not Impossible
Source: SeekingAlpha
2025-07-30 16:57:48 ET
Investment Overview
Editas ( EDIT ) is a company I have not covered for Seeking Alpha in some time - since December 2022 in fact - largely because its share price has been in near constant decline, ever since hitting highs of >$90 per share in early 2021 based on the promise of CRISPR/Cas9 gene editing technology....
Read the full article on Seeking Alpha
For further details see:
Editas Medicine: Primed For An Unlikely Comeback? It's Not Impossible
Editas Medicine Inc.
NASDAQ: EDIT
EDIT Trading
-2.57% G/L:
$2.465 Last:
588,093 Volume:
$2.60 Open:
EDIT Latest News
March 09, 2026 07:00:00 am
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
EDIT Stock Data
$174,737,401
95,568,668
0.4%
71
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
